Response to Wong et al

Affiliations

¹ Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia. Electronic address: David.Whiteman@qimrberghofer.edu.au.
² Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia.
³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

David C Whiteman et al. J Invest Dermatol. 2025 Jul.

. 2025 Jul;145(7):1818-1819.

doi: 10.1016/j.jid.2024.11.024. Epub 2025 Mar 12.

¹ Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia. Electronic address: David.Whiteman@qimrberghofer.edu.au.
² Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Australia.
³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

No abstract available

Keywords: Age-period-cohort models; Incidence; Melanoma; Sex.

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts to declare.

Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity.
Olsen CM, Pandeya N, Miranda-Filho A, Rosenberg PS, Whiteman DC. Olsen CM, et al. J Invest Dermatol. 2025 Jan;145(1):135-143. doi: 10.1016/j.jid.2024.05.011. Epub 2024 Jun 17. J Invest Dermatol. 2025. PMID: 38897542
Comment on "Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity.".
Wong ZY, Ou KQ, Wong ZN, Faderani R, Kanapathy M, Mosahebi A. Wong ZY, et al. J Invest Dermatol. 2025 Jul;145(7):1816-1818. doi: 10.1016/j.jid.2024.11.023. Epub 2025 Mar 12. J Invest Dermatol. 2025. PMID: 40072403 No abstract available.

1. Schwartz MR, Luo L, Berwick M. Sex Differences in Melanoma. Curr Epidemiol Rep 2019; 6: 112–8. - PMC - PubMed
1. Smith AJ, Lambert PC, Rutherford MJ. Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study. Br J Cancer 2021; 124: 671–7. - PMC - PubMed
1. Afshar N, Dashti SG, Mar V, Te Marvelde L, Evans S, Milne RL, et al. Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data. Int J Cancer 2024; 154: 793–800. - PubMed
1. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 2018; 19: 737–46. - PubMed
1. Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, et al. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. J Clin Med 2018; 7. - PMC - PubMed